China Resources Pharmaceutical Group Limited (03320.HK): Plans to Acquire 23.50% Equity Stake in Lier Chemical at Consideration of Approximately RMB 5.656 Billion
NewTimeSpace News: On 30 July 2026, China Resources Pharmaceutical Group Limited (03320.HK) issued an announcement. CR Shuanghe, the Group’s non-wholly-owned subsidiary, entered into share purchase agreements with Jiuyuan Group and Huacai Technology to acquire a total 23.50% equity stake in Lier Chemical for a total consideration of about RMB 5.656 billion.
The Company stated that the proposed acquisition will facilitate the industrialised commercialisation of CR Shuanghe’s synthetic biological products, and the two parties boast strong business synergies. The transaction is subject to preconditions including approvals from state-owned asset regulatory authorities and anti-monopoly review, and there is no guarantee that the transaction will be completed.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CHINARES PHARMA (03320.HK): tender launched for CR Pharmaceutical Commercial's potential issue, up to RMB5.5 billion
- CHINARES PHARMA (03320.HK): Unit completes 2026 bond issue at 1.48%
- CHINARES PHARMA (03320.HK): Pre-bid process starts on unit share issue
- CHINARES PHARMA(03320.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 2.19 billion, YoY increase of 5.26%
- CHINARES PHARMA (03320.HK):Issues 1.4 Billion Yuan 3-Year Corporate Bonds with 1.65% Coupon Rate